Idania Baladrón

Centro de Ingeniería Genética y Biotecnología — CU

Biochemistry, Genetics and Molecular Biology · Life Sciences

8h-index429citations10works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Kinase Regulation and GTPase Signaling(3), Immunotherapy and Immune Responses(3), PI3K/AKT/mTOR signaling in cancer(3), Peptidase Inhibition and Analysis(3), COVID-19 Clinical Research Studies(2)

Publications10 total

Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
ACS Pharmacology & Translational Science·2020· 45 citedOpen Access
Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in Covid-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial
2020· 5 citedOpen Access
Safety and Therapeutic Profile of a GnRH-Based Vaccine Candidate Directed to Prostate Cancer. A 10-Year Follow-Up of Patients Vaccinated With Heberprovac
Frontiers in Oncology·2019· 12 citedOpen Access
CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation
Seminars in Oncology·2018· 58 cited
Optimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
British Journal of Cancer·2015· 40 citedOpen Access
CIGB-300: A Promising Anti-Casein Kinase 2 (CK2) Peptide for Cancer Targeted Therapy
2015· 5 cited
CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research
Molecular and Cellular Biochemistry·2011· 43 cited
Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial
ISRN Obstetrics and Gynecology·2011· 42 citedOpen Access
Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies
BMC Cancer·2009· 80 citedOpen Access
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
Molecular and Cellular Biochemistry·2008· 99 cited

Frequent Co-authors

Carmen Valenzuela(10), Silvio E. Perea(7), Yasser Perera(7), Pedro López‐Saura(5), Roberto Gómez(5), Daniel F. Alonso(5), Boris Acevedo(4), Osvaldo Reyes(3), Hernán G. Fariña(3), Arielis Rodríguez(3), Ignacio Hernández(3), Margarita Solares(3), Agueda Santana(3), Alina Díaz(3), Thelvia I. Ramos(3), Luis Javier González(3), Hugo Sigman(3), Luís Herrera(3), Loida Torres(3), Gerardo Guillén(3)